Anzeige
❌
Mehr »
Dienstag, 17.11.2026 - Börsentäglich über 12.000 News
GBC-Kursziel 2,00 CAD bis Juni 2027, Kurs 0,67 CAD: Verdreifachung drin?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
10.11.Summit sheds commercial leaders ahead of ivonescimab's FDA decision
10.11.J&J readies Caplyta for FDA label expansion after 2nd phase 3 win in bipolar mania
10.11.After court win, WuXi AppTec scores removal from US list of Chinese military companies
10.11.FDA orders new eye risk be listed on a dozen GLP-1s, including Novo's Ozempic, Lilly's Zepbound
10.11.Phillips Medisize strikes deal to expand UK inhalation production
10.11.Vertex lays off 78 Crinetics staffers amid $10B integration
10.11.Insulet, Marvel Comics smash diabetes stigma with new Omnipod-powered superhero
10.11.Bayer brings factor XIa to US stroke prevention with FDA nod for 1st-in-class asundexian
09.11.Veradermics wraps phase 3 program in men with 'better-than-expected' hair growth at 1 year
09.11.FDA opens safety probe into Novartis' Zolgensma over potential tumor risks
09.11.J&J's Icotyde pill drives biologic-like efficacy in psoriatic arthritis despite high-dose miss
09.11.Lilly looks to gird Foundayo label after late-stage win in sleep apnea
09.11.Moderna moves UK commercial digs to heart of London's 'knowledge quarter'
09.11.Agentic AI Is Rewriting The Pharma Marketing Playbook
09.11.Asking More of Science: How Daiichi Sankyo Is Challenging Assumptions About the Future of Cancer Care
06.11.Actor Jeremy Pope joins ViiV's 'PrEP Wisdom' campaign to educate on long-acting PrEP options
06.11.Moderna's COVID vaccine carries stellar Q3 revenue beat
06.11.Fierce Pharma Asia-Boehringer's $7.4B SBP deal; Fresenius' sweeping biosim pact; A $1B molecular glue bet
06.11.Novartis confirms more reported tumor cases in Zolgensma patients as SMA groups seek details
05.11.ANI makes $560M play for Egetis and its approved orphan drug Emcitate
05.11.RevMed's Rasonque debut nets 'eye-popping' $198M in 5 weeks, even as exec tempers expectations
05.11.Boehringer Ingelheim brings liver health education push to the NASCAR fast lane
05.11.AstraZeneca said to offer $10B to acquire Rhythm, analysts whisper of a bidding war
05.11.VintaBio assets go on auction block as CGT viral vector demand slows
05.11.Alnylam seeks new commercial leader as Tolga Tanguler exits amid faltering Amvuttra trajectory